Core Insights - The session focuses on Teva and includes an introduction by Richard Francis, the CEO of Teva, discussing the company's current situation and outlook [2] Company Overview - Richard Francis, CEO of Teva, is present to provide insights into the company's status and future prospects [2] Industry Context - The session is part of a broader equity research initiative led by Morgan Stanley, indicating a focus on pharmaceutical industry analysis [1]

Teva Pharmaceutical Industries FY Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Date of Conference**: September 09, 2025 - **Key Speaker**: Richard Francis, CEO of Teva Core Industry Insights - **Transition Strategy**: Teva has been executing a "Pivot to Growth" strategy for over two years, transitioning from a pure-play generics company to a biopharmaceutical company, achieving 10 consecutive quarters of growth [2][4] - **Generics Business**: The generics segment is expected to represent 25% of Teva's global generics business after the loss of Revlimid generic revenues next year, indicating a shift in focus towards innovative products [42] Key Financial Metrics - **Growth Metrics**: Despite a 2% decline in the generics business in Q2 2024, Teva reported growth in gross margin, EBITDA, operating margin, and EPS, demonstrating the strength of its innovative portfolio [4] - **Revenue Targets**: Teva aims for Austedo to exceed $3 billion in revenue by 2027, driven by increased patient adherence and optimal dosing [16][17] Product Pipeline and Innovations - **Innovative Pipeline**: Teva's pipeline includes high-quality assets such as olanzapine and Uzedy, with expectations of significant market impact in treating schizophrenia [19][20] - **ICS-SABA Combination**: Teva has a $1 billion target for its dual-action rescue inhaler, with confidence stemming from the large patient population that should be on combination therapy [28][30] Market Dynamics and Competitive Landscape - **Generics Market**: Teva's generics business is positioned for low single-digit growth, supported by a robust pipeline and a transformation in manufacturing capabilities [43] - **Direct-to-Consumer Channels**: Teva is exploring direct-to-consumer cash pay channels, which could enhance value retention and patient access [9] Strategic Focus and Future Outlook - **Execution of Strategy**: Teva is in the acceleration phase of its growth strategy, focusing on innovative assets and maintaining a disciplined approach to capital allocation [51][52] - **Long-term Goals**: Teva aims for a 30% operating margin, 5% CAGR revenue growth, and a net debt/EBITDA ratio of two times by 2027 [52] Additional Considerations - **Regulatory Environment**: Teva is monitoring potential U.S. tariffs on pharmaceuticals, with a strong manufacturing footprint in the U.S. mitigating risks [7][8] - **Partnerships and Collaborations**: Teva has engaged in strategic partnerships to enhance its pipeline without significant capital investment, particularly in the GLP-1 market [48][49] This summary encapsulates the key points discussed during the conference, highlighting Teva's strategic direction, financial performance, and product pipeline developments.

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development.New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression.Emrusolmin is a small molecule that targets the alpha synuclein protein, which is believed to be pivotally involved in the pat ...

Core Viewpoint - Teva Pharmaceutical Industries Limited's stock has increased by 19.4% in the past month, driven by mixed second-quarter results where earnings estimates were beaten but sales fell short [1][2]. Group 1: Financial Performance - Teva's second-quarter results showed a 1% decline in sales on a constant currency basis, primarily due to lower sales in its global generics business [1][11]. - The company reported strong sales growth for its three innovative branded drugs: Austedo, Ajovy, and Uzedy, which collectively saw a 26% year-over-year increase in sales during the second quarter [2][3]. - Teva's U.S. generics/biosimilars business rose by 15% in 2024, although sales were nearly flat in the first half of 2025 due to lower revenues from specific generic products [12][14]. Group 2: Product Performance - Austedo sales increased by 29% in the first half of 2025, reaching $891 million, with expectations of annual revenues exceeding $2.5 billion by 2027 [4]. - Ajovy sales rose by 34% in the first half of 2025 to $117 million, with anticipated growth from patient expansion and international launches [5]. - Uzedy, launched in May 2023, achieved sales of approximately $117 million in 2024 and saw a 134% increase to $93 million in the first half of 2025 [6]. Group 3: Pipeline and Future Outlook - Teva aims to generate over $5 billion in revenues from its branded products by 2030 [8]. - The company has a promising pipeline for branded drugs, including olanzapine and duvakitug, with plans for phase III trials and new drug applications in 2025 [7]. - Teva plans to double its global biosimilars sales by 2027, with several new launches expected [13]. Group 4: Market Position and Valuation - Teva's stock is currently trading at a price/earnings ratio of 7.11, which is lower than the industry average of 11.26, indicating an attractive valuation [19]. - Despite a 14.8% decline in stock price year-to-date, the company is experiencing stock price appreciation due to improved growth prospects and a robust pipeline [16][25]. Group 5: Strategic Initiatives - The company is optimizing operations for efficiency, aiming for an adjusted operating margin of 30% by 2027 through cost savings and growth in branded drugs [24]. - Recent credit outlook upgrades from Fitch, Moody's, and S&P reflect improved growth prospects for Teva [25].

Company Overview - Teva Pharmaceutical Industries Ltd. is a leading innovative biopharmaceutical company with a strong generics business, committed to addressing patients' needs for over 120 years [2] Upcoming Events - Richard Francis, Teva's President and CEO, will present at two investor conferences in September 2025: Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 8:30 A.M. ET and BofA Global Healthcare Conference 2025 in London on September 24 at 9:00 A.M. British Summer Time [1][4] Webcast Information - A live webcast of the presentations will be available on Teva's Investor Relations website, with an archived version accessible within 24 hours after the live discussion [1]

Core Viewpoint - The EU and US tariff exemption for generic drugs is expected to significantly promote the development of the generic drug industry, particularly benefiting Ireland's pharmaceutical sector [2] Group 1: Impact on Generic Drug Industry - The original agreement clarifies that the maximum tariff on brand-name drugs imported from Europe to the US will be 15%, while generic drugs will be exempt from tariffs [2] - Generic drugs have become a crucial part of Ireland's pharmaceutical industry, with major manufacturers like Teva and Sandoz having a strong presence in the country [2] - The FDA estimates that generic drugs account for 91% of total drug sales in the US, highlighting their dominance in the market [2] Group 2: Economic Implications for Ireland - The tariff exemption for generic drugs, contrasted with the 15% tariff on brand-name drugs, will have a significant impact on Irish pharmaceutical manufacturers [2] - The EU-US agreement is likely to accelerate the trend of brand-name pharmaceutical companies, such as Johnson & Johnson and Pfizer, establishing facilities to produce generics after patent expirations [2] - The exemption will assist the Health Service Executive (HSE) in reducing drug expenditure, which was approximately €2.6 billion last year, making it the largest spending item in the healthcare budget [2]

Core Insights - Teva Pharmaceuticals has received FDA approval for a generic version of Saxenda (liraglutide injection), marking the first-ever generic GLP-1 product specifically indicated for weight loss in the U.S. market [1][2][7] - The launch of this generic is part of Teva's strategy to expand its complex generics portfolio and is the fifth first-to-market entry for the company in 2025 [2][7] - Saxenda generated annual sales of $165 million as of June 2025, indicating a significant market opportunity for Teva's generic version [2] Company Strategy - The approval and launch of the generic Saxenda align with Teva's "Pivot to Growth" strategy, emphasizing the company's commitment to complex generic medicines [7] - Teva aims to address the increasing demand for weight loss therapies in the U.S. market through this new product [7] Product Information - Liraglutide injection is indicated for adults with obesity or overweight who have weight-related medical problems, as well as for pediatric patients aged 12-17 years with obesity [3][7][8] - The product should be used in conjunction with a reduced-calorie diet and increased physical activity to achieve weight loss and maintain weight reduction [3][7] Market Context - The introduction of the generic Saxenda is expected to enhance competition in the GLP-1 therapy market, which has seen rising demand for weight loss solutions [7] - Teva's entry into this segment may influence pricing and accessibility for patients seeking weight management options [7]

Core Viewpoint - Stanley Druckenmiller, the billionaire head of Duquesne Family Office, has exited his position in Palantir Technologies, a leading AI stock, and shifted his focus to Teva Pharmaceutical Industries, which is considered one of the cheapest pharmaceutical stocks available [1][6][20] Investment Activity - Druckenmiller has completely sold his stake in Palantir, reducing his holdings from nearly 770,000 shares at the end of June 2024 to zero by the end of March 2025 [9][10] - Over the past year, Druckenmiller has added 45 securities to Duquesne's portfolio, with Teva being a significant focus, now ranking as the second-largest holding by market value [15][16] Palantir Technologies - Palantir has experienced a remarkable return of nearly 2,700% since the beginning of 2023, driven by its core platforms, Gotham and Foundry, which have unique value propositions [7][8] - Despite its strong performance, Palantir's valuation has raised concerns, with a price-to-sales (P/S) ratio around 140, significantly higher than historical norms for tech stocks [12][11] - The company has consistently exceeded Wall Street's sales and profit expectations, achieving recurring profitability ahead of estimates [9] Teva Pharmaceutical Industries - Teva's stock has gained 87% over the past two years, recovering from previous challenges, including overpayment for Actavis and litigation related to the opioid crisis [16][17] - A $4.25 billion settlement regarding opioid litigation has been agreed upon, alleviating legal uncertainties for Teva [17] - Teva is shifting focus towards brand-name drug development, with projected sales of its drug Austedo expected to reach around $2 billion in 2025 [18] - The company has significantly reduced its net debt and operating expenses, positioning itself for potential growth and earnings multiple expansion [19][20]

About AJOVY AJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit https://ww ...

Core Insights - Teva Pharmaceutical Industries reported second-quarter 2025 adjusted earnings of 66 cents per share, exceeding the Zacks Consensus Estimate of 63 cents, with an 8% year-over-year increase in adjusted earnings driven by higher operating profits [1][7] - Revenues for the second quarter were $4.18 billion, falling short of the Zacks Consensus Estimate of $4.28 billion, remaining flat year over year on a reported basis and down 1% on a constant currency basis [1][2] Revenue Performance - Revenue growth was impacted as increased sales from branded drugs such as Austedo, Ajovy, and Uzedy were offset by declining generic drug sales in both U.S. and international markets, primarily due to the exit from Japan [2] - U.S. segment sales reached $2.15 billion, a 2% year-over-year increase, driven by branded drugs, although it missed the Zacks Consensus Estimate of $2.19 billion [3] - Generic/biosimilar product revenues in the U.S. declined 6% year over year to $961 million, missing the Zacks Consensus Estimate of $1.05 billion [4] Branded Drug Sales - Austedo sales in the U.S. were $495 million, up 22% year over year, although it missed the Zacks Consensus Estimate of $501.7 million [9] - Ajovy recorded sales of $63 million, a 53% year-over-year increase, surpassing the Zacks Consensus Estimate of $50.8 million [10] - Uzedy generated sales of $54 million, up 120% year over year, driven by volume growth [10] - Copaxone sales were $62 million, down 23% year over year, but exceeded the Zacks Consensus Estimate of $48.8 million [11] International Market Performance - Europe segment revenues were $1.3 billion, a 7% year-over-year increase, driven by higher revenues from Ajovy and generic products, beating the Zacks Consensus Estimate [12] - International Markets segment sales declined 17% year over year to $495 million, missing the Zacks Consensus Estimate of $602.4 million, primarily due to the divestment in Japan [13][14] Margin and Expense Analysis - Adjusted gross margin was 54.6%, up 170 basis points year over year, attributed to higher Austedo revenues and the sale of certain product rights [15] - Adjusted operating income rose 7% year over year to $1.13 billion, with an adjusted operating margin of 27.1% [17] Guidance Updates - Teva expects total revenues in 2025 to be between $16.8 billion and $17.2 billion, raising guidance for Austedo, Ajovy, and Uzedy sales [18][19] - Adjusted EPS is projected to be in the range of $2.5 to $2.65 per share for 2025, compared to the previous expectation of $2.45 to $2.65 [19]